US – Codexis, a leading enzyme engineering company enabling the promise of synthetic biology, has completed the transfer of its CodeEvolver platform technology with Novartis. The transfer comes two years later after both companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver to develop novel performance enzymes for use in the manufacture of pharmaceutical products. This licensing move will become the third of its kind and will have Novartis use it within its facility compared to the previous ones that had…
Read MoreCodexis completes its license transfer of its codeevolver technology to Novartis for non-exclusive use
